SCHEMBL7150900

SCHEMBL7150900

COC(=O)C(Cc1ccccc1)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.56
PPARG P37231 3/20 0.53
PPARA Q07869 3/20 0.53
ATM Q13315 1/20 0.53
ALDH1A1 P00352 2/20 0.51
THRB P10828 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HSD17B10 Q99714 1/20 0.51
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
PPARD Q03181 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
PTPN1 P18031 1/20 0.48
CA12 O43570 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355177 0.87 LTA4H (0.67) PPARGPPARAPPARDNPC1RAB9A
SCHEMBL14392329 0.86 MMP8 (0.56) SRRPPARGPPARAALDH1A1HSD17B10
SCHEMBL9119394 0.86 MMP8 (0.56) SRRPPARGPPARAALDH1A1HSD17B10
SCHEMBL15451585 0.86 SRR (0.50) SRRPPARGPPARAATMALDH1A1
SCHEMBL16877217 0.85 SRR (0.70) SRRPPARGPPARAPPARD
SCHEMBL9628212 0.85 SRR (0.70) SRRPPARGPPARAPPARD
SCHEMBL2517934 0.85 SRR (0.70) SRRPPARGPPARAPPARD
SCHEMBL19024634 0.84 TSHR (0.53) SRRPPARGPPARAALDH1A1THRB
SCHEMBL28851015 0.84 PSMB5 (0.54) SRRPPARGPPARAATMALDH1A1
SCHEMBL29163290 0.84 PPARG (0.65) PPARGPPARAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109020912-B Synthesis process of C-Fos/AP-1 inhibitor 南京昊绿生物科技有限公司 2020-08-18 CN disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
US-7534894-B2 Biphenyloxy-acids WYETH (US) 2009-05-19 US disclosed
WO-2005030702-A1 BIPHENYLOXY-ACIDS WYETH (US) 2005-04-07 WO disclosed
WO-2003015736-A2 PERFUME-CONTAINING COMPOSITION QUEST INTERNATIONAL B.V. (NL) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.